Sodium cromoglycate and eformoterol attenuate sensitivity and reactivity to inhaled mannitol in subjects with bronchiectasis

Respirology

Volumn 16, Issue 1, 2011, Pages 161-166

  Briffa, Peter J ^a   Anderson, Sandra D ^a   Burton, Deborah L ^b   Young, Iven H ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b CHARLES STURT UNIVERSITY   (Australia)

Author keywords

Bronchiectasis; Eformoterol; Forced expiratory volume in 1 s (FEV 1); Mannitol; Sodium cromoglycate

Indexed keywords

CROMOGLYCATE DISODIUM; FORMOTEROL; FORMOTEROL FUMARATE; MANNITOL;

ADULT; AGED; ARTICLE; BRONCHIECTASIS; BRONCHUS REACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG SENSITIVITY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, INHALATION; ADULT; AGED; ANTI-ASTHMATIC AGENTS; BRONCHIAL PROVOCATION TESTS; BRONCHIECTASIS; CROMOLYN SODIUM; CROSS-OVER STUDIES; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MANNITOL; MIDDLE AGED; OXYGEN;

EID: 79952259303     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2010.01894.x     Document Type: Article

References (22)

1. Daviskas E, Anderson SD, Eberl S et al. Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am. J. Respir. Crit. Care Med. 1999; 159: 1843-8. (Pubitemid 29275053)
2. Mysliwiec V, Pina JS. Bronchiectasis: the 'other' obstructive lung disease. Postgrad. Med. 1999; 106: 123-31.
3. Morrissey BM. Pathogenesis of bronchiectasis. Clin. Chest Med. 2007; 28: 289-96. (Pubitemid 46654484)
4. Morrissey BM, Evans SJ. Severe bronchiectasis. Clin. Rev. Allergy Immunol. 2003; 25: 233-47. (Pubitemid 38223542)
5. Daviskas E, Anderson SD, Brannan JD et al. Inhalation of dry powder mannitol increases mucociliary clearance. Eur. Respir. J. 1997; 10: 2449-54. (Pubitemid 28048614)
6. Daviskas E, Anderson SD, Eberl S et al. The 24 hr effect of mannitol on the clearance of mucus in patients with bronchiectasis. Chest 2001; 119: 414-21. (Pubitemid 32163751)
7. Daviskas E, Anderson SD, Gomes K et al. Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum. Respirology 2005; 10: 46-56. (Pubitemid 40343762)
8. Anderson SD, Brannan J, Spring J et al. A new method for bronchial-provocation testing in asthmatic subjects using a dry powder of mannitol. Am. J. Respir. Crit. Care Med. 1997; 156: 758-65. (Pubitemid 27396412)
9. Brannan JD, Koskela H, Anderson SD et al. Responsiveness to mannitol in asthmatic subjects with exercise- and hyperventilation-induced asthma. Am. J. Respir. Crit. Care Med. 1998; 158: 1120-6. (Pubitemid 28489011)
10. Koskela H, Hyvärinen L, Brannan JD et al. Responsiveness to three bronchial provocation tests in patients with asthma. Chest 2003; 124: 2171-7. (Pubitemid 38010586)
11. Brannan JD, Anderson SD, Perry CP et al. The safety and efficacy of inhaled dry powder mannitol as a bronchial provocation test for airway hyperresponsiveness: a phase 3 comparison study with hypertonic (4.5%) saline. Respir. Res. 2005; 6: 144.
12. Anderson SD, Daviskas E, Turton J et al. Prevalence of bronchoconstriction in patients with bronchiectasis assessed prior to treatment with a dry powder preparation of mannitol. Eur. Respir. J. 2007; 30 (Suppl. 51): 306s.
13. Brannan JD, Gulliksson M, Anderson SD et al. Inhibition of mast cell PGD2 release protects against mannitol-induced airway narrowing. Eur. Respir. J. 2006; 27: 944-50. (Pubitemid 44911107)
14. Quanjer PH, Tammeling GJ, Cotes JE et al. Lung volumes and forced ventilatory flows. Eur. Respir. J. 1993; 6: 5-40. (Pubitemid 23116782)
15. Koskela H, Hyvärinen L, Brannan JD et al. Sensitivity and validity of three bronchial provocation tests to demonstrate the effect of inhaled corticosteroids in asthma. Chest 2003; 124: 1341-9. (Pubitemid 37290044)
16. Rodwell LT, Anderson SD. Hyperosmolar saline aerosol challenge: a useful tool in the management of subjects with cystic fibrosis. Paediatr. Pulmonol. 1996; 21: 282-9.
17. Yager D, Shore S, Drazen JM. Airway luminal liquid: sources and role as an amplifier of bronchoconstriction. Am. Rev. Respir. Dis. 1991; 143: S52-4.
18. Brannan JD, Gulliksson M, Anderson SD et al. Evidence of mast cell activation and leukotriene release after mannitol inhalation. Eur. Respir. J. 2003; 22: 491-6. (Pubitemid 37098931)
19. Echazarreta AL, Dahlen B, Garcia G et al. Pulmonary gas exchange and sputum cellular responses to inhaled leukotriene D(4) in asthma. Am. J. Respir. Crit. Care Med. 2001; 164: 202-6. (Pubitemid 34001282)
20. Anderson SD. Single dose agents in the prevention of exercise-induced Asthma: a descriptive review. Treat. Respir. Med. 2004; 3: 365-79.
21. Anderson SD, Caillaud C, Brannan JD. β2-agonists and exercise-induced asthma. Clin. Rev. Allergy Immunol. 2006; 31: 163-80.
22. Solèr M, Joos L, Bolliger CT et al. Bronchoprotection by salmeterol: cell stabilization or functional antagonism? Comparative effects on histamine- and AMP-induced bronchoconstriction. Eur. Respir. J. 1994; 7: 1973-7. (Pubitemid 24366286)